A clinical algorithm integrating PD-L1 expression, tumor-infiltrating lymphocyte (TIL) density, and HPV subtype can guide monoclonal antibody (mAb) therapy by stratifying patients into groups with different expected responses to PD-1/PD-L1 blockade. This evidence concerns the gene CD274 and neoplasm.